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Hepatocellular Carcinoma (HCC) in the United States: Current Epidemiological
Trends:
The incidence of HCC has almost tripled since the early 1980s in the United States where it is the fastest rising cause of cancer-related deaths 1 . According to population based Surveillance Epidemiology and End Results registry data, the overall HCC age adjusted incidence rates for liver and intrahepatic ducts cancer is as high as 8 per 100,000 underling population in 2010 (Fig. 1 ) of which at least 6 per 100,000 related to HCC. Men are at approximately three times higher risk than women. Asian men (i.e., Chinese, Korean, Filipino, and Japanese) have the highest age-adjusted incidence rates. However, the largest proportional increases have occurred among Hispanics followed by blacks and non-Hispanic whites, whereas the lowest proportional increases have occurred among Asians. In contrast to Asians/Pacific Islanders, HCC incidence rates are reported to be higher among Hispanics born in the United States than among foreign-born Hispanics 
Most HCC risk factors (chronic infection with hepatitis B (HBV) and/or C virus (HCV)
and alcoholic liver disease) operate by promoting the development of cirrhosis.
Exceptions are rare in HCV-related HCC and mostly represent cases with at least bridging hepatic fibrosis 5 . While most cases of HBV-related HCC also occur in the background of cirrhosis (as high as 85% in some studies) 6 , HBV can cause HCC in the absence of advanced fibrosis or cirrhosis. Although there are several mechanisms for non-alcoholic fatty liver disease-non-alcoholic steatohepatitis (NAFLD-NASH) related HCC conceivably in the presence of mild or no fibrosis 7 , there are no systematic studies to confirm or quantify this contention 8 . Indirect measures of severity of hepatic fibrosis such as degree of liver stiffness using elastography is associated with risk of HCC 9 .
The risk of developing HCC in cirrhosis patients varies with the underlying condition.
The highest 5-year cumulative risks are seen in HCV cirrhosis (17% in the West and 30% in Japan), hemochromatosis (21%), HBV cirrhosis (10% in the West and 15% in Asia), alcoholic cirrhosis (8%-12%), and biliary cirrhosis (4%) 10 5 Nevertheless, the summary HCC incidence rate in these regions is approximately 0.02 per 100 person-years in inactive carriers (HBsAg-positive but with normal levels of alanine aminotransferase, ALT), 0.3 in subjects with chronic HBV without cirrhosis, and 2.2 in subjects with HBV related compensated cirrhosis. On the other hand, cohort studies estimated the incidence rates of HCC among subjects with chronic HBV infection in East Asian countries to be 0.2 per 100 person-years in inactive carriers, 0.6 per 100 person-years for those with chronic HBV infection without cirrhosis, and 3.7 per 100 person-years for those with compensated cirrhosis.
Several demographic (male sex, older age, Asian or African ancestry, family history of HCC), viral (higher levels of HBV replication; HBV genotype; longer duration of infection; co-infection with HCV, HIV, or HDV), and environmental factors (exposure to aflatoxin, heavy intake of alcohol or tobacco) increase HCC risk among individuals with chronic HBV 2 . HBV viral load appears to be an important determinant of HCC risk. The incidence of cirrhosis and HCC increased in proportion to the serum level of HBV DNA 12 in Asian countries as well as Alaska 13 . HBV genotypes also seem to affect clinical outcomes. In North America and Western Europe, individuals with genotype D had a higher incidence of HCC than those with genotype A. Some data associate genotype B HBV with the development of HCC in young carriers without cirrhosis 14;15 . Mutations in the region of the HBV genome that encode the basal core promoter 16 , have been associated with increased HCC risk, whereas those in the precore region have been associated with decreased HCC risk 17 .
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Aflatoxin causes a mutation at serine 249 in the tumor suppressor p53 that was detected in 30%-60% of HCC tumor samples collected from individuals in aflatoxinendemic areas, most of whom also had HBV infections. Aflatoxin associated mutation is rarely detected in HCC cases diagnosed in the US.
HCV: HCV infection is associated with a 15-to 20-fold increase in risk for HCC compared with HCV-negative subjects. The rate of HCC in cohort studies of HCVinfected persons ranges from 1% to 3% over 30 years of chronic infection. Once HCVrelated cirrhosis is established, HCC develops at an annual rate of 1%-8% (average 3.5%). Risk factors for HCC in HCV-infected individuals include male sex, co-infection with HBV or HIV, diabetes, obesity, and high level of alcohol consumption.
HCV viremia of any level is a strong risk factor for HCC compared to no viremia, however, while few studies reported a correlation between HCV viral load levels and risk of progression to cirrhosis 18 . Cirrhosis causes glucose intolerance and type 2 diabetes, and also leads to HCC, making it difficult to interpret the association between HCC and diabetes especially in case-control and cross-sectional studies. However, this bias is less likely to be present in longitudinal studies; several cohort studies also showed a similar association between diabetes and HCC. This association is less consistent in areas with a high incidence of HBV infection than in other regions. Factors that change HCC risk among patients with diabetes are not clear, but it has been suggested that long diabetes duration and high HbA1C increase the risk, while metformin treatment decreases HCC risk 31 .
Obesity: A meta-analysis of 26 prospective cohort studies, including 25, 337 primary liver cancer cases demonstrated that a BMI ≥ 25 kg/m2 as well as a BMI ≥ 30 kg/m2 were associated with an increased risk of primary liver cancer. The summary relative risk for a 5-unit increment in BMI was 1.39 kg/m2 (95% CI: 1.25-1.55) with the most pronounced increase in risk among persons with a BMI >32 kg/m2. The association between BMI and liver cancer was independent of geographic location, alcohol consumption, or history of diabetes. However, obese males had a higher risk of primary liver cancer than obese females. Furthermore, the association between increasing BMI and HCC was much stronger in individuals with concomitant HCV infection than in persons with HBV infection. Recently, a genetic polymorphism of the patatin-like phospholipase domaincontaining (PNPLA3) protein has been shown to be associated with an increase in hepatic fat deposition as well as an increase in the risk of HCC development 32 . This and other genetic markers may serve as a part of predictive algorithms to identify high risk groups for surveillance or chemoprevention. . There is evidence for a synergistic effect between heavy ingestion of alcohol and HCV infection and, to a lesser extent, HBV infection on HCC risk; similar synergism may be present with diabetes.
These factors presumably operate together to promote cirrhosis and further increase the risk in individuals with cirrhosis 34;35 .
Cigarette Smoking:
The association between cigarette smoking and HCC has been inconsistent with few studies finding a positive association and others finding no associations. Among studies reporting positive associations, several found that effects were limited to only those with HBV or HCV infection 36 .
Burden of HCC related to the major risk factors in the US
Estimates of relative risk such as risk ratios or odds ratios for any of the individual HCC risk factors do not describe their contribution to HCC burden, which is also driven by the prevalence of the risk factor in the general population. Population attributable fraction (PAF) accounts for both an estimate of relative risk as well as prevalence of a given risk factor in the population, and it describes the proportional reduction in disease that would occur if exposure to a risk factor were to be eliminated.
Metabolic syndrome is likely to have the greatest PAF ( 37 .
Therefore despite having the lowest relative risk among the risk factors examined, the high prevalence of diabetes/obesity translate into a high attributable fraction. surveillance in patients at risk for HCC is intended to detect small, treatable cancer (tertiary prevention). The section below focuses on primary and secondary prevention.
HBV Vaccination Program
National HBV vaccination programs have been the most successful prevention strategy in reducing the incidence of HCC in HBV-endemic areas. These programs have dramatically reduced the prevalence of HBV (16% to 1.4% in China, 9.8% to 1.3% in Taiwan, and 9.3% to 0.9% in Spain) with a concomitant decrease in the incidence of
HCC. Since the implementation of the universal vaccination program for newborns in
Taiwan in 1986 to early 1990's, the average annual incidence of HCC in children between 6 and 14 years of age has fallen by 65 to 75% 38 .
In these regions, HBV is the most important risk factor for HCC, and universal vaccination programs, with almost 100% penetration, have been successful in decreasing the rate of chronic HBV in the general population. In other regions (e.g., Spain) where HBV is mainly spread by different parenteral routes, a decline in HBV likely resulted from screening of blood products and use of disposable syringes and needles. However, there are still ~400 million individuals chronically infected with HBV in the world-a group that will not benefit from immunization and remains at increased risk for HCC. Of these, an estimated ~800,000 -1.4 million live in the U.S.
Antiviral Treatment
There is moderately strong evidence that successful antiviral therapy for HBV or HCV substantially reduces but does not eliminate the risk of HCC in patients with viral 
HBV Treatment
One randomized controlled clinical trial evaluated efficacy of antiviral treatment on longterm clinical outcomes in patients with HBV. In a large Taiwanese study, patients with chronic HBV infection who also had cirrhosis or advanced fibrosis were randomly assigned to receive 100 mg of lamivudine per day or placebo for up to 5 years; the incidence of HCC was significantly reduced in the lamivudine group as compared with the placebo group (3.9% vs. 7.4%; hazard ratio, 0.49; P=0.047) 39 ; this trial was terminated early (after a median duration of treatment of 32.4 months) because of a significant difference between treatment groups in the number of end points reached.
Papatheodoridis et al. systematically reviewed data on HCC incidence from 21 studies including 2881 patients with HBV who were treated with medium-term nucleos(t)ide analogues (lamivudine was the initial treatment in 19, emtricitabine in one, and adefovir in one study) 40 . Only three of the 21 studies included untreated HBV patients followed for at least 24 months (one from the only randomized controlled trial on this topic as described above). A total of 168 (4.3%) patients receiving nucleos(t)ide analogue therapy were diagnosed to have HCC during a mean/median follow-up of 40 (24-102) months. In the three studies with untreated controls, which were all of high quality and large, the rate of HCC was significantly lower in the treated (22/779, 2.8%) than in the untreated patients (34/534, 6.4%, p = 0.003). Of note, most of these data on the effect of HBV treatment on the risk of HCC come from studies that used lamivudine. The use of all oral anti-viral agents in patients with cirrhosis is associated with improved virological, biochemical and clinical parameters at 1-year with tenofovir and entecavir being the most efficacious 43 .
The effect of interferon on HCC incidence in patients with chronic HBV has also been evaluated in several studies and meta-analyses [44] [45] [46] . Most of the data suggest that interferon treatment decreases overall HCC incidence in sustained responders. Most studies included in this systematic review were from Asia. Given the fact that rates of HCC are higher in Asian populations than in European or U.S. populations, the absolute benefit of SVR on HCC risk may have been overestimated. Collectively however, these data show a moderate protective effect of treatment-related SVR on the development of HCC among HCV-infected persons. However, the absolute risk of HCC does not revert to baseline levels among those with cirrhosis, older age, high α-fetoprotein levels, low platelet counts, high fibrotic stage and diabetes 48;49 .
HCV Treatment
Furthermore, HCC incidence in nonresponders to initial antiviral therapy is not reduced by maintenance IFN therapy. Newer and more effective therapies may further stem the risk of HCC in HCV infected persons.
Treatment of Non-alcoholic Fatty Liver Disease
There is currently no direct evidence to show that treatment for NAFLD/NASH by any modality (including bariatric surgery) can reduce this risk. Several agents may have 
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, assuming an SVR rate of ~80%, antiviral treatment will decrease cases of cirrhosis . However, issues related to patient consent, buy-in, and reimbursement may reduce its overall effectiveness. Furthermore, the degree to which increased identification will result in treatment with new, highly potent yet expensive treatment remains to be seen 57 . The success of the CDC's plan will likely be contingent upon the use of efficient and effective means of entering and retaining individuals in HCV care-steps that will need more focused efforts in the nearterm. 
